patients. These PILs demonstrated the ability to eliminate papillomatous tissue. Relatedly, a T cell manufacturing method holds promise for developing cell-based therapies for widespread use in chronic HPV 6/11-related conditions—including RRP and anogenital condyloma. Notably, the ability to isolate and expand antigen-specific lymphocytes from non-cancerous growths represents an exciting advancement in the field of adoptive cell therapy—potentially paving the way for treating a broader range of non-malignant diseases.

The Center for Immuno-Oncology and the Surgical Oncology Program of the NCI, Center for Cancer Research are actively seeking industry partners to support the clinical development and commercialization of this approach. It is particularly well-suited for biotech firms focused on T cell therapies or addressing HPV-related diseases. Strategic collaboration could accelerate market entry and unlock significant value in an area with high unmet medical need.

''This Notice is in accordance with 37 CFR 404.4 Authority to grant licenses.''

NIH Reference Number: E–143–2024–0.

Related Technologies: N/A.

Product Type: Infectious Disease | Immunology.

Therapeutic Area(s): Therapeutic.

Development Stage: Pre-clinical (*in vivo* validation).

Publications:

- Bai K, Norberg SM, Sievers C, Meyer T, et al. Durable response in a patient with recurrent respiratory papillomatosis treated with immune checkpoint blockade. (*https://doi.org/10.1002/hed.27144*).

Patents: PCT/US2025/051640, filed October 20,2025.

Potential Commercial Applications

- Immunotherapy for chronic HPV-related conditions such as RRP and anogenital condyloma.
- Development of personalized T cell therapies targeting HPV 6 or HPV 11 infections.
- Generation of T cell receptor (TCR) libraries for research and therapeutic purposes.

Competitive Advantages

- Addresses lack of approved systemic therapies for chronic HPV 6 or 11-related conditions.
- Potential to treat both non-cancerous and cancerous HPV-related conditions.
- PILs represent novel therapeutic approach.
- Drug development for RRP may qualify for regulatory incentives due to the rarity of the disease.
- Increased therapeutic efficacy from the ability to produce oligoclonal T cell populations.
- Selective expansion of T cells with high specificity for HPV 6 or HPV 11 antigens.
- Methodology applicable to both therapeutic and preventative treatments for chronic HPV infections.

Collaboration Opportunity: Researchers at the NCI seek licensing and/or co-development research collaborations for PIL in treatment for chronic HPV6/11-associated diseases.

Dated: July 13, 2026.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2026–14347 Filed 7–15–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Population Sciences and Epidemiology Integrated Review Group; Analytics and Statistics for Population Research Panel B Study Section.

Date: August 13–14, 2026.

Time: 10:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Ivan Tadeu Rebustini, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–2467, *ivan.rebustini@nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel; Contract Research Organization for the NIAAA Medications Development Clinical Trials Network.

Date: August 18, 2026.

Time: 10:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate contract proposals.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Alicia Mariel Jais, PHMD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Bethesda, MD 20892, (301) 435–3343, *mariel.jais@nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel; Contracts: Clinical Research Products Management Center (CRPMC).

Date: August 25, 2026.

Time: 10:00 a.m. to 1:30 p.m.

Agenda: To review and evaluate contract proposals.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Vishakha Sharma, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Bethesda, MD 20892, 301–594–2297, *vishakha.sharma@nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR–25–444: Cancer Center Support Grants.

Date: August 26–27, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Eun Ah Cho, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496–359, *EunAh.Cho@nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: July 13, 2026.

Sterlyn H. Gibson,

Program Specialist, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–14343 Filed 7–15–26; 8:45 am]

BILLING CODE 4167–05–P